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Original Excluder component overlap from
proximal or distal extension during initial repair
not correlated with aneurysm sac shrinkage
Gale L. Tang, MD,a,b Mark F. Fillinger, MD,c and Jon S. Matsumura, MD,a Chicago, Ill; Seattle, Wash;
and Dartmouth, NH
Objectives: The original abdominal Excluder (W.L. Gore & Associates, Flagstaff, Ariz) endoprosthesis has been associated
with late aneurysm sac expansion over time from transgraft ultrafiltration of serous fluid. This has been treated by relining
the graft with original or low-permeability components. We asked whether additional component overlap of the original
graft material resulting from proximal or distal extensions placed at the time of initial repair would influence the rate of
late aneurysm sac expansion in the absence of endoleak.
Methods: Computed tomography (CT) scans from subjects (n  120) receiving the original endoprosthesis from the
Excluder pivotal trial were measured for total distance of original graft overlap (including contralateral gate, proximal
extension, or distal extension overlap) based on reformatted CT scans. This was compared to change in aneurysm sac
diameter and volume (as measured in independent laboratories) at the latest time point available. Patients were omitted
if they weremissing CT scan data (n 10), their graft was explanted for endoleak (n 2), they underwent an intervention
for endoleak and did not have diameters available after their intervention (n 3), or if they had a continued endoleak that
could account for an increase in aneurysm sac diameter (n 11). This left 27 patients with more overlapping components
than the required contralateral limb/gate overlap (mean follow-up time 40.6  17.0 months) and 67 patients with
required gate overlap (mean follow-up time 46.2  15.9 months).
Results: Subjects with increased component overlap (mean overlap 87.1 mm  57.4 mm) were not protected from
aneurysm sac expansion when compared to those with the minimum required gate overlap (mean overlap 31.2 mm 3.4
mm). There was no association of total distance of overlap with aneurysm sac size change by diameter or volume (r2 
0.00034, P  .86 for diameter and r2  0.0019, P  .68 for volume). Increasing percentage of overlap within the
aneurysm sac was likewise not associated with aneurysm sac decrease in diameter (r2 0.0028, P .61). Few patients had
large percentages of original graft overlap (mean 26.2%  14.1% for the increased overlap group and 18.6%  5.5% for
the required overlap group, P  .0097).
Conclusion: Partial graft overlap involving multiple original components from proximal and distal extensions is not
protective against aneurysm sac expansion due to transgraft ultrafiltration. This suggests that transgraft ultrafiltration is
not impeded by having partial double layers of original material. All patients who received the original Excluder and have
late aneurysm sac expansion in the absence of endoleak should have as complete relining as feasible with low permeability
components if sac shrinkage is the surrogate goal. ( J Vasc Surg 2009;49:1409-15.)The original abdominal Excluder endoprosthesis (W.L.
Gore&Associates, Flagstaff, Ariz) was initially approved by
the Food&Drug Administration (FDA) in 2001 following
a pivotal controlled trial demonstrating safety and efficacy
in aneurysm exclusion while preventing aneurysm rupture.1
Longer term follow-up demonstrated that over a third of
the 30,000 patients who received this endoprosthesis un-
derwent late aneurysm sac expansion, most in the absence
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doi:10.1016/j.jvs.2009.02.209of any detectable endoleak.2-4 A better understanding of
the factors that lead to delayed sac expansion would help
management of the thousands of patients worldwide who
received the original device.5
Explanted devices were found to be surrounded by
proteinaceous acellular material,6 suggesting that ultrafil-
tration of serum was occurring through the original ex-
panded polytetrafluroethylene (ePTFE) graft. These find-
ings resulted in a modification of the endoprosthesis graft
material to include a low-porosity film layer. The modified
device was commercially introduced in July 2004 and ap-
pears in midterm studies to have less associated sac expan-
sion than the original device.7
Goodney and Fillinger6 noted that no proteinaceous
material was found around the contralateral gate graft
overlap in explanted original material grafts and theorized
that a double layer of graft material might be protective of
the ultrafiltration effect. A recently described technique to
detect endoleak using delayed magnetic resonance (MR)
contrast imaging also did not demonstrate endoleak in
regions of graft overlap.8 Relining either with original or
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to decrease aneurysm sac expansion in patients who re-
ceived the original endoprosthesis,6,9 supporting the idea
that increased graft-graft overlap within the aneurysm sac is
protective against the ultrafiltration effect. It remains un-
clear why some patients develop delayed aneurysm sac
expansion and others do not.
We hypothesized that patients who received compo-
nents in addition to the main body and contralateral limb
(either proximal or distal extensions at the time of initial
implantation), and thereby had a higher percentage of
graft-graft overlap would have a decreased risk for aneu-
rysm sac expansion. In order to test this hypothesis, we
analyzed computed tomography (CT) scans from patients
who received the original device in the Excluder pivotal
trial for length of graft overlap and compared this to the
change in diameter or volume of the aneurysm sac.
METHODS
We analyzed orthogonal slice reformations at 1 mm
intervals (Preview M2S, previously Medical Metrix Solu-
tions, West Lebanon, NH) of CT scans from 120 of the
273 patients who had the original Excluder implanted in
the Excluder pivotal trial. This was a randomly chosen
subset used as the control group in the controlled trial
against the low-porosity graft, and therefore had reformat-
ted CT scans available for analysis. Overlap was defined as at
least two pieces of graft within one another. All patients had
overlap between the contralateral gate of the main body
device and the contralateral docking limb. Additional over-
lap occurred from implanted components such as any prox-
imal extension or distal limb extension placed within the
main body/ipsilateral limb component or within the con-
tralateral limb. Each patient was measured for total distance
of graft overlap in millimeters of the entire treated segment.
If the length could not be directly measured from the
reformatted CT scans (secondary to poor image quality,
generally resulting from reformatted CT scans obtained
from scanned cut films or from large slice intervals), the
overlap length was derived from the devices known to be
implanted into that patient and the measured overall length
covered by stent graft.
Graft overlap length for the entire treated segment was
compared to change in maximal aneurysm sac diameter (as
measured by the core laboratory during the original trial) at
the latest time point available (see Tables I and II for the
follow-up time points for each patient) or aneurysm sac
volume in cubic centimeters (as measured from three-
dimension [3-D] CT scan reformations) at the latest time
point available (Tables I and II). If a patient had under-
gone a secondary intervention which resolved an en-
doleak, the change in aneurysm sac diameter was calcu-
lated as the latest time point diameter minus the sac
diameter on the scan immediately preceding the second-
ary intervention (n  15).
Additionally, the percentage of overlap within the an-
eurysm sac was calculated by measuring the length of
overlap within the aneurysm sac and dividing the result bythe total length of device within the aneurysm sac (com-
prised of the length of main body within the sac added to
the length of each leg within the sac). The total surface area
of the graft within the aneurysm sac was estimated by
adding p*d*h (surface area of a cylinder where d  diam-
eter of the graft and h length of each component) for the
main body and each limb. Surface area of overlap within the
aneurysm sac was estimated by adding p*d*h of each
region of graft overlap. The percentage of surface area
overlapped within the aneurysm sac was then estimated by
dividing the surface area of overlap by the total surface area
of the graft.
Statistical analysis was performed using t test for pro-
portions for the analysis of patients on antiplatelet or anti-
coagulation therapy with increasing or decreasing sac diam-
eters and for the comparison of percentage of graft overlap
within the aneurysm sac between the required overlap and
increased overlap groups. Spearman rank correlations were
performed for comparisons between groups with sac over-
lap and diameter (or volume) change as the variables. An
exploratory P value of less than .05 was considered to be
significant.
RESULTS
Patients were chosen for analysis if they had reformation
CT scan follow-up for at least 12 months. Patients were
excluded from the analysis if they were missing CT scan data
(n7) or if the reformationCT scandid not include the distal
end of the stent graft (n  2), their graft was explanted for
endoleak (n  2), they underwent an intervention for an
endoleak and did not have diameters available after their
intervention (n  3), or if they had a continued endoleak of
any type that could account for an increase in aneurysm sac
diameter (n  11). This left 27 patients with more overlap-
ping components than the required contralateral limb/gate
overlap (increased overlap group) and 67 patients with the
minimum required overlap (required gate overlap group).
Nine patients had proximal extensions (9.6% of the total 94
patients analyzed) and 19 patients had limb extensions (20.2%
of the analyzed patients).
An increase in graft overlap length was not correlated
with a decrease in maximal aneurysm sac diameter, r2 
0.00034, P  .86, degrees of freedom  92 (Fig 1). The
mean graft overlap length for the increased overlap group
was 87.1  57.4 and for the required gate overlap group
was 31.2 3.4. As aneurysm sac volume has been found to
be more sensitive than sac diameter for changes in aneu-
rysm sac morphology,4,10 we also compared length of graft
overlap with aneurysm sac volume which was available at 24
months for the majority of patients. One patient with more
than the required overlap had diameter but not volume
measurements available and was omitted from the volume
analysis, leaving 25 patients with increased overlap and 66
patients with required overlap. An increased length of graft
overlap was likewise not correlated with a decrease in
aneurysm sac volume, r2  0.0019, P  .68, degrees of
freedom  91 (Fig 2).
s.
sm sac
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occur primarily when the original graft material is within
the aneurysm sac and not when the original graft material is
opposed to the vessel wall. Therefore, scans were also
analyzed for the length of graft overlap in contact with the
aneurysm sac as a percentage of total length of graft within
the aneurysm sac to derive a percentage of aneurysm sac
overlap. One of the 2 patients whose reformatted CT scan
did not include the distal end of the stent graft was mea-
sured for the percentage of overlap within the aneurysm
sac, although the total length of overlap was not able to be
measured or derived. Themean percentage of aneurysm sac
overlap for the increased overlap group was 26.2% 14.1%
and the required gate overlap group was 18.6%  5.5%
(P  .0097). Only 3 patients had more than 40% graft
overlap within the aneurysm sac. The results are presented
in Fig 3; there is no correlation with decrease in aneurysm
Table I. Increased overlap group data
Subject Age
Antiplt/
anticoag Devices
Interventio
other
features
1 74 No R ipsi, R extend, prox
extend
Extend
2 69.7 No L ipsi, L extend  3
3 54.9 Yes R ipsi, R extend
4 70.6 No L ipsi, prox extend
 2
5 58 No R ipsi, R extend Embolized
6 78.8 No R ipsi, prox extend Embolized
7 75.8 No R ipsi, L extend Embolized
8 73.3 Yes R ipsi, prox extend
9 71.8 No R ipsi, L extend
10 63.2 No L ipsi, R extend
11 71.1 No L ipsi, B extend (R 14
 12, L 10  7)
Branch lumb
12 79.1 Yes R ipsi, L extend
13 72.7 Yes R ipsi, R extend Unknown ty
14 73.7 No R ipsi, R extend
15 75 No R ipsi, prox extend
16 83 No R ipsi, prox extend
17 71.1 No R ipsi, R extend Embolized
18 72.8 Yes R ipsi, prox extend Explant (no
19 60.7 No L ipsi, prox extend Explant (no
20 65.3 Yes L ipsi, R extend
21 77.9 No R ipsi, R extend
22* 74.6 Yes L ipsi, limb extend
23 72.4 Yes L ipsi, R extend Embolized
24 80 No R ipsi, R extend
25 69 No R ipsi, L extend
26 65.1 No R ipsi, R extend Embolized
27 64.4 No R ipsi, prox extend, R
extend  2, L
extend
28 78.8 No L ipsi, L extend  2 Embolized
Mean 71.2
St Dev 6.9
Antiplt/anticoag, Patient discharged on antiplatelet or anticoagulation thera
change in diameter from initial (or immediate pre-intervention) maximal sac
from initial (or immediate pre-intervention) sac volume in cubic centimeter
*Unable to determine limb overlap due to incomplete CT scan, but aneurysac diameter (r2  0.0028, P  .61, degrees of freedom 93). The percentage of aneurysm sac overlap derived from
estimating surface areas was highly correlated with that
calculated using lengths, r2  0.87, suggesting that using
overlap length is a reasonable surrogate measure for vulner-
able graft surface.
Anticoagulation or antiplatelet therapy at the time of
discharge was recorded for the trial patients. There was
no significant difference between the percentage of pa-
tients on antiplatelet/anticoagulation therapy at the
time of discharge whose aneurysm increased in diameter
(49.0%) or decreased in diameter (41.5%, P  .47).
Table I includes details of the patients who had addi-
tional overlap. Table II includes details of the patients
who had the required overlap.
DISCUSSION
Partial graft overlap from multiple original Excluder
Overlap
% Sac
overlap
Orig sac
size
(mm)
Diam
change
(mm)
F/U
(mo)
Vol
change
(cc)
F/U
(mo)
104 34.3% 58.4 6 27.9 34.1 0
140 8.4% 54.4 8.2 60.4 19.3 23.8
67 24.5% 54.8 2.3 59.9 29.6 23
63 21.6% 67.5 5.4 57.8 45.1 25.3
75 28.2% 70.3 5.2 40 68.7 3.2
63 43.0% 71.2 1.8 12.9 92.4 0
39 13.2% 56.5 14.5 24.1 73.8 24.1
61 24.0% 55.6 11.9 59.5 21.8 23.6
75 34.8% 48.8 8.1 23.5 26.6 23.5
83 18.3% 51.0 7.7 60.5 21.1 23.9
152 47.1% 57.0 2.8 60.6 34.2 24.1
71 26.0% 53.1 2.7 60.2 13.5 23.3
62 22.6% 53.7 6.1 48.1 no data 24
68 20.9% 49.2 3.5 61 2.7 24.7
62 25.5% 59.9 6.8 23.4 125.8 23.4
60 17.3% 58.7 4.2 35.7 7.7 24.8
69 15.2% 53.1 11.9 41.2 27.2 5.7
55 12.9% 57.0 3.6 36.1 10 24.2
55 27.5% 54.5 20.5 26.7 184.4 26.7
79 33.8% 47.7 1.4 49.1 1.6 23.5
73 14.8% 74.4 18.7 35.8 92.2 23.4
35 22.6% 68.5 1.9 60.9 6.6 23.9
50 19.0% 59.9 3 13.6 16.2 0
79 24.3% 55.3 17.7 36.4 77.6 24.5
105 35.8% 51.7 7.6 59.3 4.6 24.2
75 13.3% 48.9 0.9 10.9 15.1 10.9
342 80.8% 57.2 0 23.9 93.9 23.9
124 24.1% 51.6 1.2 48.1 8.2 11.7
87.1 26.2% 57.1 1.7 41.3 10.0 19.2
57.4 14.1% 7.2 8.6 17.1 61.4 9.0
t sac size, initial maximal aneurysm sac diameter inmillimeters;Diam change,
ter in millimeters; F/U, follow-up in months; Vol change, change in volume
overlap percentage available.ns/
ar
pe
leak)
leak)
py; Ini
diamecomponents placed during initial endovascular aortic
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Subject Age
Antiplt/
anticoag Devices
Interventions/
other
features Overlap
% Sac
overlap
Orig sac
size
(mm)
Diam
change
(mm)
F/U
(mo)
Vol
change
(cc) F/U (mo)
29 69 No R ipsi 29 20.1% 47.2 7.5 60 27 24.2
30 65.1 Yes R ipsi 33 22.0% 52.1 0 60.1 16.2 24.3
31 84.3 No R ipsi Embolized 30 14.2% 67.6 2.8 13.2 31.8 13.2
32 54.5 No R ipsi 33 19.2% 63.4 0 61.2 27.1 25
33 71.4 No R ipsi Explant (no leak) 28 13.1% 58.0 7.5 49.6 4.8 24.1
34 82.5 Yes R ipsi 33 18.3% 62.4 24.1 59.3 10.7 12.5
35 70 Yes R ipsi Type II resolved 29 14.7% 56.4 0.1 58 2.9 23.2
36 78.3 No R ipsi 32 23.8% 82.3 5.7 23.4 5.1 23.4
37 84.5 Yes R ipsi 22 12.4% 52.7 13.2 60.9 85.3 24.6
38 72.3 Yes R ipsi Embolized 30 17.3% 69.9 5.4 45.5 10.7 0
39 69.2 No R ipsi 28 24.1% 50.7 5.8 60.7 11.8 24.4
40 54.3 Yes R ipsi 31 27.3% 48.5 17.2 63.1 17.5 24.7
41 80.5 Yes R ipsi 35 20.7% 54.5 1.4 52.8 1.9 11.8
42 85.7 No R ipsi Embolized 29 17.2% 69.0 17.9 38.7 40 13.9
43 71.6 Yes L ipsi 28 19.2% 55.6 20.9 60.9 33.9 24.6
44 91.3 Yes L ipsi 30 22.7% 54.5 0.5 61.3 5.2 24.8
45 83.8 No R ipsi 32 15.7% 66.9 2.1 24.3 10.5 24.3
46 76 No R ipsi 32 15.3% 50.2 3.4 23.8 0.2 23.8
47 74.1 No L ipsi 30 21.3% 50.4 6 48.5 7.3 23.8
48 57.5 No R ipsi 31 17.0% 49.0 7.9 64.8 9.4 24.2
49 73.7 No R ipsi 34 26.3% 54.0 5.2 48.6 0.5 24.6
50 76 No L ipsi 34 37.8% 53.3 3.1 60.1 2.7 23.7
51 67.5 No R ipsi 32 16.1% 50.2 3.3 61.7 24.6 24.5
52 75.5 No R ipsi 36 22.5% 58.0 14.5 60.1 22.5 24.9
53 64.4 No R ipsi 27 12.3% 59.9 11.2 62.6 9.1 24.6
54 68 No R ipsi 35 18.6% 60.4 0.8 60.1 26.1 23.7
55 78.8 Yes R ipsi 35 21.7% 62.6 1.6 60 2.8 24.4
56 71.4 No R ipsi 31 16.7% 48.3 3.4 27.1 8.8 27.1
57 66.5 Yes R ipsi 35 22.9% 61.8 6.7 60 77.6 23.9
58 69.2 Yes R ipsi 38 24.4% 45.7 2.8 60.1 0.9 23.9
59 65.6 No R ipsi 30 19.9% 48.5 9.1 60.1 0.2 23.6
60 74.9 Yes R ipsi 32 10.9% 44.2 24.3 60.3 5.7 23.8
61 71.7 No R ipsi 26 13.0% 68.8 39 59.8 53.3 23.7
62 83.2 Yes R ipsi 28 14.7% 65.1 7.6 64.6 3 25.4
63 62.4 Yes R ipsi Type II resolved 26 13.4% 51.3 8.5 23.9 70.5 23.9
64 78.5 Yes R ipsi Embolized 26 10.9% 49.6 11.1 22.9 50.9 0
65 62.7 No L ipsi 32 18.6% 64.4 5.8 26.2 44.9 26.2
66 77.2 Yes R ipsi Embolized 27 4.8% 60.0 8.8 33.3 11.5 0
67 66.8 No R ipsi Embolized 23 4.4% 71.4 4.6 28.5 10.1 16.1
68 85.7 Yes R ipsi Embolized 32 20.4% 72.0 7.1 28.3 16.8 15.4
69 66.1 No R ipsi 33 18.6% 62.3 1.6 23.3 5.9 23.3
70 75.2 No R ipsi 27 14.5% 73.1 1.6 23.9 3 23.9
71 74.2 Yes L ipsi 33 20.4% 52.6 18.2 23.9 35.8 23.9
72 66.5 Yes L ipsi 35 24.0% 68.5 2.6 48.6 8.1 13.1
73 67.1 No R ipsi 28 15.2% 52.0 2.6 25.6 4.2 25.6
74 74.9 Yes L ipsi 37 24.5% 53.8 9.5 61.3 25 28
75 79.1 No L ipsi 36 23.1% 59.0 7.5 49.2 9.6 25.2
76 74.8 Yes R ipsi 28 16.1% 69.8 3.1 24.6 10.9 24.6
77 74 Yes R ipsi 39 26.9% 52.0 13.2 46.8 0.3 21
78 68.2 Yes L ipsi 32 21.0% 52.1 3.9 46.7 8.2 22.9
79 77.7 No R ipsi Embolized 30 23.4% 54.3 4.8 31.5 4.4 6.4
80 87.1 No R ipsi Embolized 32 18.0% 54.2 18.5 59.4 32.8 20.9
81 48.9 Yes R ipsi 31 15.6% 47.0 1.3 59.4 44.9 11.7
82 78.4 Yes R ipsi 29 19.1% 51.9 1.1 23.4 6.3 23.4
83 69.8 No L ipsi 29 13.7% 64.3 1.7 61.2 28.9 24.4
84 83.2 Yes R ipsi Explant (no leak) 33 15.9% 57.1 13.4 24.2 64.2 24.2
85 80.8 Yes 29 8.3% 72.1 1.5 38.2 25.9 24.6
86 68.9 Yes R ipsi 30 18.4% 61.7 4.5 59.9 3 24
87 78.9 No R ipsi Embolized 33 22.9% 47.1 1.6 46.9 4.8 11.1
88 71.4 Yes R ipsi 29 14.5% 49.8 4.5 59.9 1.2 24.4
89 71.5 No R ipsi 33 18.2% 61.8 3.9 59.7 48.5 24.1
90 70.3 Yes R ipsi 31 16.0% 50.0 0.7 23.1 9.4 23.1
91 76.6 Yes L ipsi 34 25.8% 46.9 11.9 61 33.9 22.4
92 52 Yes R ipsi 32 13.4% 57.8 1.7 24.3 1.1 24.3
ter; F
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sac expansion, suggesting that other patient-related fac-
tors are responsible for which patients will develop de-
layed aneurysm sac expansion. Neither aneurysm sac
diameter nor volume was associated with length of graft
overlap. The percentage of overlap of total graft length
within the aneurysm sac was likewise not correlated with
change in aneurysm sac diameter. The hypothesis that
graft overlap should be protective against aneurysm sac
expansion was not fully tested, however, as the sample
lacked a significant proportion of patients with large
lengths of overlap.
A probable explanation for these findings is that the
majority of the overlap in this group of patients was not in
contact with the aneurysm sac where the ultrafiltration
effect may be assumed to be the greatest. The average
percentage of actual overlap within the aneurysm sac was
only 26.2%  14.1% for the group of patients with more
than gate overlap, with 10 of 27 patients having no addi-
Table II. Continued
Subject Age
Antiplt/
anticoag Devices
Interventions/
other
features Ov
93 80.2 Yes R ipsi 3
94 69.8 No R ipsi Unknown 3
95 70.1 No R ipsi Type II resolved 3
Mean 69.8 3
St Dev 9.7
Antiplt/anticoag, Patient discharged on antiplatelet or anticoagulation ther
diameter from initial (or immediate pre-intervention) maximal sac diame
pre-intervention) sac volume.
Fig 1. Original Excluder aneurysm sac diameter change not cor-
related with increased overlap. Length of overlap of patients (n 
67) with baseline overlap from the contralateral gate (white circles)
and patients (n  27) with additional overlap from extra compo-
nents (black squares) plotted against change in aneurysm sac diam-
eter does not show any correlation between increased length of
overlap and decrease in aneurysm sac diameter.tional overlap beyond the contralateral gate within theaneurysm sac. This was because these patients received
additional components as proximal or distal extensions.
Therefore, these findings do not contradict that graft relin-
ing, where more than 90% of the portion of the graft within
the aneurysm sac is overlapped, may be an effective strategy
for preventing or treating ultrafiltration.
Graft relining strategies have included use of an
aortic cuff and two iliac limbs, two iliac limbs deployed
up into the main body of the original endoprosthesis,
and two iliac limbs deployed into the two limbs of the
original endoprosthesis.6,9 Kougias et al9 described 3
patients who had aneurysm sac expansion in the absence
of demonstrable endoleak after implantation of the orig-
inal Excluder device. Sac pressure measurements from a
translumbar approach were equivalent to systemic pres-
sures. All 3 patients were treated by relining using an
aortic cuff and two iliac limbs, 2 with low-porosity compo-
nents and 1with original components. All 3 had sac shrinkage
with 12-month follow-up.9Goodney andFillinger6 described
their experience of relining 9 patients with aneurysm sac
% Sac
overlap
Orig sac
size
(mm)
Diam
change
(mm)
F/U
(mo)
Vol
change
(cc) F/U (mo)
24.3% 61.5 20.3 50.4 43.3 24
23.2% 58.3 14.8 36.3 3.3 23.7
22.3% 50.5 17.9 44.7 28.2 24.2
20.8% 54.2 7.3 40.0 5.1 23.6
5.0% 5.8 12.5 14.9 27.4 0.7
nit sac size, initial maximal aneurysm sac diameter; Diam change, change in
/U, follow-up; Vol change, change in volume from initial (or immediate
Fig 2. Original Excluder aneurysm sac volume change not corre-
lated with increased overlap. Length of overlap of patients (n 67)
with baseline overlap from the contralateral gate (white circles) and
patients (n  26) with additional overlap from extra components
(black squares) plotted against change in aneurysm sac volume does
not show a correlation between increased length of overlap and
decrease in aneurysm sac volume.erlap
4
2
7
3.3
2.2
apy; Iexpansion in the absence of demonstrable endoleak after
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three of the above strategies were used. They reported
6-month follow-up for 5 patients, all of whom had aneu-
rysm sac shrinkage or stabilization in size after relining. The
remaining 4 patients had less than 6-month follow-up, and
the effect of relining on their aneurysm sac size was not
reported. Taken together with the data from the present
study, there is compelling rationale that, when indicated,
relining should be performed with the goal to reline as
much endograft surface within the aneurysm sac as is safely
feasible.
Antiplatelet or anticoagulation therapy at the time
of discharge did not correlate with aneurysm sac expan-
sion, suggesting that this is not a factor affecting ultra-
filtration. Unfortunately, data regarding anticoagulation
alone was not available for these patients, preventing us
from analyzing this as an independent variable. Another
possible patient-related factor would be dynamic motion
at the proximal neck, although this would result in an
intermittent type I endoleak with thrombus rather than
proteinaceous material found within the sac.
A possible hypothesis is that fluid exchange across the
original graft membrane is a dynamic equilibrium, with
more fluid exchanged out into the sac in the patients with
aneurysm sac expansion then returned into the systemic
circulation. Patients who had sac regression would have
more fluid return than egression. Patients with stable sac
size would have equivalent amounts exchanged in and out.
In this hypothesis, having additional graft overlap might
bias the fluid exchange rate towards absorption over time.
The results presented here, however, suggest that small
amounts of original graft overlap are not sufficient to cause
Fig 3. Percentage aneurysm sac overlap not correlated with sac
diameter change. Patients with additional overlap from baseline
(n 26, black squares) who had higher percentage of graft overlap
within the aneurysm sac were not protected from aneurysm sac
expansion. They did have a significantly higher percentage of graft
overlap (26.2%  14.1% vs 18.6%  5.5%, P  .0097) than
patients with baseline overlap from the contralateral gate (white
circles). Few patients had extensive graft overlap.sac regression, and that small amounts of increased overlapwas not among the patient-related factors which promoted
sac regression in this cohort.
Although sac expansion due to ultrafiltration has for
the most part been benign,11 several complications are
theoretically possible. The most significant is missing an-
other type of endoleak as the true cause for aneurysm sac
expansion. Nevertheless, aneurysm sac rupture, venous
compression, ureteral obstruction, bowel obstruction, and
loss of proximal or distal seal zone4 are also potential
complications from continued sac expansion.
Short areas lined by double layers of original material
do not impede transgraft ultrafiltration sufficiently to pre-
vent aneurysm sac expansion. As with all patients who
undergo endovascular aneurysm repair (EVAR), those who
received the original Excluder need to have continued long
term surveillance. Patients who have late aneurysm sac
expansion that is deemed to require reintervention and
have no detectable endoleak by thorough imaging investi-
gation should have as complete relining as feasible with low
permeability components.
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